Cover Image

Validation of MELD 3.0 and ReMELD-Na scoring systems: a German clinical cohort study

The Model for End-Stage Liver Disease (MELD) score, introduced in 2002, has since been refined. MELD 3.0, launched in 2023 in the United States, improves mortality prediction by incorporating sex and albumin. Since March 2025, Germany started to use reMELD-Na to improve prioritization of patients on...

Full description

Saved in:
Bibliographic Details
Main Authors: Putri, Aghnia Jolanda (Author) , Jiang, Decan (Author) , Czigány, Zoltán (Author) , Mehrabi, Arianeb (Author) , Büchler, Markus W. (Author) , Merle, Uta (Author) , Michalski, Christoph (Author) , Husen, Peri (Author)
Format: Article (Journal)
Language:English
Published: 25 September 2025
In: Langenbeck's archives of surgery
Year: 2025, Volume: 410, Issue: 1, Pages: 1-9
ISSN:1435-2451
DOI:10.1007/s00423-025-03846-x
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00423-025-03846-x
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00423-025-03846-x
Get full text
Author Notes:Aghnia J. Putri, Decan Jiang, Zoltan Czigany, Arianeb Mehrabi, Markus Wolfgang Buechler, Uta Merle, Christoph Michalski, Peri Husen
Description
Summary:The Model for End-Stage Liver Disease (MELD) score, introduced in 2002, has since been refined. MELD 3.0, launched in 2023 in the United States, improves mortality prediction by incorporating sex and albumin. Since March 2025, Germany started to use reMELD-Na to improve prioritization of patients on the waiting list for liver transplantation (LT). This study compares the performance of original MELD, MELD-Na, MELD 3.0 with and without albumin, and reMELD-Na for patients waitlisted for LT in a large German transplant center.
Item Description:Online veröffentlicht am 25. September 2025
Gesehen am 16.01.2026
Physical Description:Online Resource
ISSN:1435-2451
DOI:10.1007/s00423-025-03846-x

Similar Items